Introduction:
What kind of company is PME?
Why is PME's business so stable?
What are the prospects for PME's development?
What key information does PME's annual report reveal?
Pro Medicus (ASX: PME), a company operating in both the technology and healthcare sectors, has long maintained a valuation above the industry average. However, as the company releases its financial reports, it coincides with short-term turbulence in the US stock market, leading to significant selling pressure on its shares. People have begun to worry about risks such as slowing performance and stock price collapses.
However, the company's latest financial report once again proves the value represented by its high valuation, and the stock price also broke through the previous high after the report. A close look at the report content shows that Pro Medicus (ASX: PME) not only has the characteristics of high growth rate and high gross margin of a technology company, but also has long-term cooperation with large customers in the medical industry and excellent financial statement data. Australian finance has also shared PME's outstanding performance many times before ("What's wrong with this popular blue-chip technology and medical stock that lost all its gains in two days?", "More than 50% increase in the year, gross margin over 100%, this 'dark horse' stock in the medical sector has come out"). Taking this financial report opportunity, this article will take investors to comb through the current situation and future development dynamics of Pro Medicus (ASX: PME) again.
What kind of company is Pro Medicus (ASX: PME)?
PME is a SaaS company focused on medical imaging software, mainly providing a full set of software and services for hospitals and medical imaging centers. The company's main income comes from the imaging software system Visage 7 and the internal management system Visage RIS of medical institutions. Among them, Visage 7, which is technologically ahead of its peers, is the company's main competitive advantage, with its proprietary streaming technology and fully cloud-based architecture. This allows Visage 7 to provide fast and seamless imaging services and can be deployed on a large scale. Compared with traditional systems, Visage 7 does not require local hardware, reducing management complexity and improving security, accurately solving the pain points of medical institutions.
Why is Pro Medicus's (ASX: PME) business so stable?Companies typically sign multi-year long-term contracts with clients, and due to the high cost of switching systems in medical institutions, once a system is selected, it involves extensive long-term training of staff to achieve deployment. Setting aside the cost of switching, the software provided by PME is also industry-leading, so there has been virtually no long-term customer churn. Therefore, in this financial report, the customer retention rate remains the familiar 100%.
What is the development prospect of Pro Medicus (ASX: PME)?
The market for Pro Medicus (ASX: PME) is mainly in Australia and the United States, with the United States accounting for approximately 90% of total revenue. In Australia, it is almost in a monopolistic position, with large hospitals and private imaging centers, such as the two largest medical imaging institutions in Australia, I-Med Radiology and Lumas, being long-term clients of PME. There is virtually no possibility of expanding to more clients.
In the United States, PME has a considerable room for imagination. Although at first glance, 11 out of the top 20 hospitals in the United States have become long-term clients of PME, PME currently holds only about 7% of the market share in the entire U.S. market. With the trend of more and more large institutions becoming PME clients, better network effects will be beneficial to PME's expansion speed, and network effects have already been reflected in this year's financial report.
What key information did PME's annual report reveal?
As mentioned above, the network effects of PME's sales in U.S. medical institutions and the competitiveness of the products are very evident in this financial report:
Revenue increased by 29.3%; reaching 160 million Australian dollars
EBITDA increased by 35.3%;
Net profit after tax increased by 36.5%Profit Margin Aspects:
- The gross margin increased from 101% to 103%.
- The EBITDA margin improved from 67.2% to 69.5%.
*Note: The reason for the gross margin exceeding 100% is that PME has a very small number of clients, sales are virtually cost-free, and coupled with PME's substantial cash reserves, it has engaged in low-risk investments to earn interest. PME has a long-term surplus of cash, and these investments are also long-term, hence they are considered part of the company's ongoing business.
In the fiscal year 24, the company secured 9 contracts with a total value of at least AUD 245 million. This has been the most successful year for PME to date. The most notable of these is a 10-year, AUD 140 million contract with Baylor, Scott and White, which is the largest non-profit healthcare system in Texas, USA, and one of the largest healthcare systems in the country, ranking in the top 30. The AUD 140 million contract is also the largest one PME has ever secured.
Industry Competitive Landscape Trends:
Such successful sales are inseparable from the technological transformation that leads the competition. The most critical trend at present is the shift of medical institutions towards cloud computing, a trend that was not initially favored but is now stratifying the competitive landscape faster than the market expected.
Traditional suppliers are facing significant difficulties at this step, with slow transformation speeds. Although some claim they can do it, they cannot provide purely cloud-based solutions. Hybrid cloud and local system solutions are not only not fully cloud-secured but also increase operational costs by managing dual systems, which goes against the original intention of the transformation.
On the other hand, some small-scale emerging imaging companies, while they can provide purely cloud-based solutions, their technical level is still stuck at the 2D stage. PME has already transitioned to the 3D era, and with a comprehensive full-process software suite, PME continues to demonstrate a clear competitive advantage.In conclusion,
Although PME has recently reported strong financial performance, maintaining a 30% annual growth rate amidst its substantial business scale poses a significant challenge for the company. However, the Australian finance and investment research team maintains a positive outlook on PME's future. While it may be somewhat difficult to sustain such rapid growth through organic means, PME still has "trump cards" in terms of external investments and mergers and acquisitions.
In the first half of this year, PME's investment of $5 million in Elucid Bioimaging, an AI company based in Boston, USA, may be the first step in further deepening its focus in this direction. Not only can it effectively utilize a substantial cash surplus, but it can also strengthen its competitive moat, helping it to continue penetrating the remaining medical imaging market in the United States at a high speed. Therefore, overall, PME remains a rare high-quality growth stock in both the Australian technology and healthcare sectors, deserving of long-term attention from investors.
When making any investment, please consider the applicability of the information contained in this article based on your personal investment goals, financial situation, or personal needs, make decisions cautiously, and bear the risks yourself.
Add Your Comment